X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New GAO report: Some hospitals participating in 340B may not be eligible for the program

By Nicole Longo  |    January 14, 2020
The Government Accountability Office (GAO) released a new report on 340B hospital eligibility compliance and made a number of alarming observations that underscore the need for more accountability...   Read More

Nearly 50% of brand medicine spending goes to the supply chain and others

By Holly Campbell  |    January 9, 2020
Nearly 50% of total spending on brand medicines – the sum of all payments made at the pharmacy or paid on a claim to a health care provider – went to the supply chain and other entities in 2018,...   Read More

340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients

By Nicole Longo  |    August 20, 2019
Congress created the 340B program to help safety-net providers, like federally-funded safety net clinics, access discounts on prescription medicines for vulnerable or uninsured patients....   Read More

Study finds hospitals continue to mark up medicines up to 500% of their cost

By Holly Campbell  |    July 9, 2019
A new analysis from the Moran Company found hospitals continue to charge, on average, five times their cost for medicines, driving up cost sharing and premiums for patients across the country....   Read More

Fresh data show, yet again, 340B is growing while charity care dwindles at many 340B hospitals

By Nicole Longo  |    May 16, 2019
There has been broad acknowledgement in Congress and by the Administration, as well as by patient groups and some hospitals, that the 340B program is not working as Congress intended. Yet little...   Read More

New study finds hospitals continue to push patients to costlier outpatient settings

By Holly Campbell  |    May 13, 2019
A new study from the Health Care Cost Institute found that, for commercially insured patients, almost 50 percent of medicines administered by physicians, including treatments for diseases like...   Read More

340B continues to drive shift in site of care for physician-administered medicines to more expensive hospital settings

By Nicole Longo  |    April 5, 2019
Is 340B benefiting the vulnerable, uninsured patients it was designed to help? Evidence continues to show otherwise. An updated analysis from Berkeley Research Group (BRG) is the latest to build...   Read More

New study finds hospitals prescribe more medicines, and more expensive medicines, after joining 340B program

By Nicole Longo  |    December 18, 2018
Data and analyses continue to show the 340B program influences prescribing trends at 340B hospitals – ultimately costing patients and our health care system more money. The Government...   Read More

New study finds some hospitals mark up medicine prices at least 700 percent

By Holly Campbell  |    September 5, 2018
A new analysis from The Moran Company found nearly one in five hospitals marks up medicine prices 700 percent or more. With this 700 percent markup, a $150 medicine purchased by a hospital could...   Read More

New analysis finds 340B medicine sales hit record high in 2017 and continue to grow as a share of total drug spending

By Nicole Longo  |    August 20, 2018
How big is the 340B program, and what share of the prescription medicine market does it represent? Those are popular questions of late as stakeholders discuss ways to improve the 340B program. In...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

Subscribe to Email Updates